drugset / Trial / NCT06489028
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III)
Phase 3
Active not recruiting
250 enrolled
RHEACELL GmbH & Co. KG
FGK Clinical Research GmbH · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The aim of this clinical trial is to investigate the efficacy and safety of allo-APZ2-CVU, administered topically on therapy-resistant non-healing CVUs compared to placebo.
Timeline
- Start
- 2024-12-26
- Primary completion
- 2027-04
- Completion
- 2027-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | allo-APZ2-CVU | Cell therapy | — | Topical |